A Boceprevir Failure in a Patient Infected with HCV Genotype 1G: Importance and Limitations of Virus Genotyping Prior to HCV Protease-Inhibitor-Based Therapy
Free accessCase reportFirst published online May, 2013
A Boceprevir Failure in a Patient Infected with HCV Genotype 1G: Importance and Limitations of Virus Genotyping Prior to HCV Protease-Inhibitor-Based Therapy
A patient classified as HCV-1a-positive by both LiPA Siemens 2.0 and Abbott RealTime HCV Genotype II was instead found to be infected with HCV-1g, as determined by phylogenetic analysis of NS3 sequences. HCV-1g NS3 sequences available to date naturally harbour the resistance substitution T54S, plus P131S and L135F changes, located in the highly conserved NS3 positions within the boceprevir-binding site, as determined by structural modelling. HCV-1g NS3 sequences show some similarities to HCV-4 and are poorly responsive to interferon/ribavirin and to boceprevir/telaprevir; this patient was also a null-responder to boceprevir treatment. Baseline genotypic resistance testing may provide crucial information for the management of first-generation protease-inhibitor-based regimens, including both HCV genotype/subtype and natural resistance.
References
1.
GhanyM.G., NelsonD.R., StraderD.B., ThomasD.L., SeeffL.B.An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology2011; 54: 1433–1444.
2.
ChevaliezS.Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect2011; 17: 116–121.
3.
KiefferT.L., DeM.S., BartelsD.J.Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS ONE2012; 7: e34372.
4.
De MeyerS., DierynckI., GhysA.Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the realize trial. Hepatology2012; 56: 2106–2115.
5.
HalfonP., LocarniniS.Hepatitis C virus resistance to protease inhibitors. J Hepatol2011; 55: 192–206.
6.
SarrazinC., ZeuzemS.Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology2010; 138: 447–462.
7.
SorianoV., VispoE., PovedaE., LabargaP., BarreiroP.Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother2012; 13: 313–323.
8.
CentoV., MirabelliC., SalpiniR.HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS ONE2012; 7: e39652.
9.
KiefferT.L., SarrazinC., MillerJ.S.Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology2007; 46: 631–639.
10.
McHutchisonJ.G., EversonG.T., GordonS.C.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med2009; 360: 1827–1838.
11.
SarrazinC., KiefferT.L., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology2007; 132: 1767–1777.
12.
ChevaliezS., Bouvier-AliasM., BrilletR., PawlotskyJ.M.Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS ONE2009; 4: e8209.
13.
NakanoT., LauG.M., LauG.M., SugiyamaM., MizokamiM.An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int2012; 32: 339–345.
14.
CentoV., De LucaF., Di MaioC.Characterization of baseline NS3 protease polymorphisms and drug resistance development in HCV-1-infected patients starting a protease-inhibitor-containing regimen. Antivir Ther2012; 17Suppl 1: A98.
15.
SusserS., WelschC., WangY.Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology2009; 50: 1709–1718.
16.
BrachoM.A., SaludesV., MartroE., BargalloA., Gonzalez-CandelasF., AusinaV.Complete genome of a European hepatitis C virus subtype 1g isolate: phylogenetic and genetic analyses. Virol J2008; 5: 72.
17.
Abdel-HamidM., El-DalyM., MolnegrenV.Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol2007; 88: 1526–1531.
18.
BartelsD.J., ZhouY., ZhangE.Z.Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis2008; 198: 800–807.
19.
ColsonP., PurgusR., BorentainP., GerolamiR.Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors. J Clin Virol2012; 53: 178–180.
20.
Fonseca-CoronadoS., Escobar-GutierrezA., Ruiz-TovarK.Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naive infected individuals. J Clin Microbiol2012; 50: 281–287.
21.
ValletS., VironF., HenquellC.NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther2011; 16: 1093–1102.
